Jyong Biotech Ltd. Ordinary Shares
NASDAQ:MENSBiotechnology
Healthcare
$1.86 -1.41%
-$0.02 today
- Market cap
- $141.41M
- Beta
- 2.08
- P/E (TTM)
- -25.1
- EPS (TTM)
- -$0.06
52W Low $1.43High $67.00
Volume 0.07M
Average 0.10M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$3.04M
FY 2025 · Annual
Investing Cash Flow
-$13.51M
FY 2025 · Annual
Financing Cash Flow
$17.63M
FY 2025 · Annual
+786.1% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (4.2M) | (6.63M) | (4.4M) | (3.02M) | (4.67M) |
| Depreciation & Amortization | 122K | 123K | 127K | 120K | 100K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 0 | 0 | 0 | 0 |
| Change in Working Capital | 1.24M | 2.94M | 1.12M | (1.49M) | 20.74M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 21K | (28K) | (2K) | 1K | (1K) |
| Other Working Capital | 1.22M | 2.97M | 1.12M | (1.49M) | 20.74M |
| Other Non-Cash Items | 849K | 599K | 554K | 761K | (19.21M) |
| Operating Cash Flow | (1.98M) | (2.97M) | (2.6M) | (3.62M) | (3.04M) |
| Capital Expenditures | (137K) | (246K) | 0 | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (1.83M) | (292K) | 0 | 0 | (16.87M) |
| Sales of Investments | 664K | 1.93M | 95K | 0 | 16.87M |
| Other Investing Activities | 0 | 0 | 0 | 0 | (13.51M) |
| Investing Cash Flow | (1.31M) | 1.39M | 95K | 0 | (13.51M) |
| Debt Repayment | (1.35M) | 3.61M | 2.47M | 2.2M | (24K) |
| Common Stock Issued | 0 | 0 | 0 | 0 | 17.77M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (35K) | (276K) | (445K) | (213K) | (114K) |
| Financing Cash Flow | (1.38M) | 3.33M | 2.03M | 1.99M | 17.63M |
| Effect of Forex Changes | 67K | (31K) | (54K) | (7K) | (8K) |
| Net Change in Cash | (4.61M) | 1.72M | (532K) | (1.64M) | 1.08M |
| Free Cash Flow | (2.12M) | (3.22M) | (2.6M) | (3.62M) | (3.04M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$4.7M
+ D&A$100.0K
+ Stock-Based Comp$0
+ Deferred Tax$0
+ Working Capital$20.7M
- Other Non-Cash-$19.2M
= Operating Cash Flow-$3.0M
- Capex$0
= Free Cash Flow-$3.0M
Analysis
FY2025 free cash flow is -$3.0M. FCF conversion is 65.1% of net income. Operating cash flow was -$3.0M, with capex of $0. The largest bridge item is Working Capital at $20.7M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 20-F | 20-F filing | May 15, 2026 | |
| NT 20-F | NT 20-F filing | Apr 29, 2026 | |
| SC 13D | SC 13D filing | Apr 24, 2026 | |
| 3 | Initial statement of beneficial ownership | Apr 14, 2026 | |
| 3 | Initial statement of beneficial ownership | Apr 8, 2026 |
Does MENS generate free cash flow?
Jyong Biotech Ltd. Ordinary Shares (MENS) generated -$3.04M of free cash flow in fiscal 2025.
How much operating cash flow does MENS produce?
Operating cash flow was -$3.04M, before capital expenditures of $0.00.
Continue the stock analysis
Jump to another research area for this company.